Skip to main content
Premium Trial:

Request an Annual Quote

ABL Acquires Assets of Evivar Medical

NEW YORK (GenomeWeb News) – Advanced Biological Laboratories, a Luxembourg-based developer of informatics tools for personalized medicine, today announced that it has acquired all of the assets of Evivar Medical for an undisclosed amount.

The acquisition includes Melbourne, Australia-based Evivar's hepatitis B and C virus web-based decision support tools for clinicians and associated viral genome analysis systems SeqHepB and SeqHepC, its intellectual property portfolio, and all related commercial arrangements and operations. The SeqHepB and SeqHepC systems are used for hepatitis B and C therapy management and can be used to identify mutations present in the infected persons, including predicting resistance levels to commercially available drugs, the firms said.

"Our acquisition of Evivar Medical assets will add value and allows ABL to further expand its Virology portfolio from HIV to include Hepatitis disease management," ABL President and CEO Chalom Sayada.

The Evivar tools will complement ABL's existing data tools including its TherapyEdge, ViroScore, and DeepChek products.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.